share_log

RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $451

Benzinga ·  Nov 6 00:51  · Ratings

RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Sector Perform and raises the price target from $437 to $451.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment